Hememics is a venture-backed biotechnology company that has developed a cellphone-sized POC device to pathogens in less than one minute. Due to a patented process for stabilizing antibodies on their proprietary chip, this technology does not require refrigeration. Coupled with its simplicity of operation, the device can be used anywhere - in the field or at bedside - to provide answers in seconds at the point of triage. The initial device in development is a point-of-care panel for STI. Inova Strategic Investments, the venture capital fund for the Inova Health System, is another significant investor in Hememics.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/11/19 | $2,500,000 |
AMVI Partners | undisclosed | |
| 05/25/23 | $2,000,000 | Seed 2 |
TEDCO | undisclosed |
